Uniqure (NASDAQ:QURE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The firm currently has a $79.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 12.34% from the stock’s current price.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other equities analysts have also commented on the stock. Robert W. Baird began coverage on shares of Uniqure in a research report on Thursday, March 28th. They issued an “outperform” rating and a $85.00 price objective for the company. HC Wainwright set a $73.00 price objective on shares of Uniqure and gave the company a “buy” rating in a research report on Monday, July 8th. Piper Jaffray Companies set a $80.00 price objective on shares of Canopy Growth and gave the company a “buy” rating in a research report on Friday, April 12th. BidaskClub upgraded shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Janney Montgomery Scott restated a “buy” rating on shares of Uniqure in a research report on Tuesday, June 11th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $78.18.
Uniqure (NASDAQ:QURE) last posted its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.03). Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. The business had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $2.00 million. On average, research analysts expect that Uniqure will post -3 earnings per share for the current year.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of Uniqure stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $58.38, for a total transaction of $467,040.00. Following the completion of the sale, the chief executive officer now directly owns 421,730 shares in the company, valued at $24,620,597.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christian Klemt sold 1,546 shares of Uniqure stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $57.18, for a total transaction of $88,400.28. Following the sale, the insider now owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,546 shares of company stock valued at $1,556,820. 2.91% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in QURE. Vivo Capital LLC bought a new stake in Uniqure during the first quarter valued at approximately $10,757,000. 683 Capital Management LLC lifted its position in Uniqure by 10.3% during the fourth quarter. 683 Capital Management LLC now owns 1,085,000 shares of the biotechnology company’s stock valued at $31,270,000 after purchasing an additional 100,900 shares during the last quarter. OppenheimerFunds Inc. lifted its position in Uniqure by 5.2% during the first quarter. OppenheimerFunds Inc. now owns 1,817,534 shares of the biotechnology company’s stock valued at $108,416,000 after purchasing an additional 90,391 shares during the last quarter. FIL Ltd lifted its position in Uniqure by 23.3% during the first quarter. FIL Ltd now owns 419,392 shares of the biotechnology company’s stock valued at $25,017,000 after purchasing an additional 79,209 shares during the last quarter. Finally, Sanders Morris Harris LLC bought a new stake in Uniqure during the second quarter valued at approximately $3,084,000. Institutional investors and hedge funds own 60.10% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Read More: 52-Week High/Low Prices For Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.